Brainstorm Health: Spark Gene Therapy, Meatless Meat, Flu Vaccine and Egg Allergies

Brainstorm Health: Spark Gene Therapy, Meatless Meat, Flu Vaccine and Egg Allergies

Luxturna is a single injection that works by delivering 150 billion viral vector particles containing a correct copy of the RP65 gene to retinal cells, restoring the patient's ability to make the missing enzyme.

Federal health officials have approved the nation's first gene therapy for an inherited disease, a treatment that improves the sight of patients with a rare form of blindness.

The FDA Wednesday approved Spark Therapeutics Inc.'s voretigene neparvovec-rzyl (Luxturna), the first gene therapy for inherited vision loss caused by faulty gene mutations.

It's the first gene therapy approved in the United States for a disease caused by mutations in a specific gene, and only the third gene therapy ever approved. The condition affects between 1,000 and 2,000 people in the United States.

Spark said Tuesday that it won't be releasing the price until early next year. As reported by the Associated Press, Lovelace, from Kentucky, was among several patients urging the FDA to approve the treatment. "Spanning the course of ten years, the research conducted at CHOP's Center for Cellular and Molecular Therapies laid the groundwork for this revolutionary gene therapy". High was joined by Jean Bennett, MD, PhD, F.M. Kirby professor of Ophthalmology at the Perelman School of Medicine at the University of Pennsylvania's Scheie Eye Institute, and Albert M. Maguire, MD, a professor of Ophthalmology at Penn Medicine and an attending physician at CHOP, who served as a Principal Investigator of the therapy's clinical trials.

Next year the agency plans to issue guidance documents that will provide instructions for companies developing gene therapies for specific diseases, including "more efficient parameters" than now exist. "There are more than 250 genes involved in vision and we hope that this may pave the way for the development of treatment for other inherited retinal diseases/causes of congenital blindness".

In the Phase 3 study, 27 of 29 treated patients had meaningful improvement in their ability to see, according to the Lancet report. The most common adverse reactions from treatment with Luxturna included eye redness (conjunctival hyperemia), cataract, increased intraocular pressure, and retinal tear. So we can guess at why Spark didn't release theirs: the cost of this treatment is likely to be mind-boggling. Those results confirmed more than a decade's worth of research. "I believe gene therapy will become a mainstay in treating, and maybe curing, many of our most devastating and intractable illnesses", he noted.

"We're at a turning point when it comes to this novel form of therapy and at the FDA, we're focused on establishing the right policy framework to capitalize on this scientific opening", Gottlieb noted. FDA Commissioner Scott Gottlieb said in a statement.



Related Posts

Nasralla Calls Honduras President Impostor
However, the European Union election observers have stated they did not encounter any irregularities in the process. Opposition leaders have accused government security forces of firing into barricades and peaceful protests.

WH Temporarily Removes Petition Tool From Website Until Late January
The total budget of the White House for 2018 is $55m and its information technology budget for the year is $4.94m. The White House announced that "We the People" website will be suspended temporarily until a new site is set up.

Get a copy of psychedelic haunted house Layers of Fear on Humble
The store will provide a key that is redeemable on Steam, and the game is playable on Windows, macOS, and Linux. Usually available for $24.99 on the Humble Store, Layers of Fear is free to claim for the next two days .

Baird Initiates Coverage on Cimarex Energy (NYSE:XEC). What May be Next?
Capital One Financial reissued an "overweight" rating on shares of Cimarex Energy in a research note on Wednesday, November 8th. The rating was upgraded by Jefferies to "Buy" on Wednesday, May 25. (NYSE:XEC) on Thursday, December 8 to "Overweight" rating.

UBS Analysts Give Oracle (ORCL) a $55.00 Price Target
After $0.55 actual EPS reported by Oracle Corporation for the previous quarter, Wall Street now forecasts 12.73 % EPS growth. The figure allows investors to understand how effectively Oracle Corporation is able to convert its money into net income.

Defender reveals why he rejected a move to the Premier League
Terry ended his 19-year spell with Chelsea at the end of last season and opted to join Villa during the summer transfer window. Chelsea lie in third place in the table, 14 points behind runaway leaders Manchester City and three behind Manchester United .

Power outage brings Atlanta airport to a standstill
Southwest Airlines told passengers to keep checking the airline's app and website to get updates on flights early Monday morning. Global flights to Hartsfield were diverted to other Atlanta-area airports, US Customs and Border Protection said.

Today's Hot Mover - Eli Lilly and Company, (NYSE: LLY)
Following the completion of the transaction, the insider now owns 123,084,104 shares in the company, valued at $10,856,017,972.80. Shares have moved $3.75 over the past month and more recently, $0.82 over the past week heading into the earnings announcement.

Today On Track Innovations Ltd. (OTIV) Stock Reaches 52-Week High
The stock witnessed 100.88% gains, 78.91% gains and 83.21% gains for the 1-month, 3-month and 6-month period, respectively. The stock of On Track Innovations Ltd . (NASDAQ: OTIV ) earned "Buy" rating by Northland Capital on Wednesday, July 19.

NY Trooper Critically Injured After Getting Hit on the LIE
State police say Trooper Gallagher had stopped to help a motorist who had broken down when the accident occurred. The driver that struck the trooper did stop and is cooperating with investigators, authorities said.

© 2015 ExpressNewsline. All Rights reserved.